Tekla Life Sciences Investors
NYSE:HQLAsset Management
+$0.11 today
- Market cap
- $585.96M
- Beta
- 0.73
- P/E (TTM)
- 2.8
- EPS (TTM)
- $6.52
- Dividend yield
- 11.35%
Volume 0.12M
Average 0.11M
HQL Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Tekla Life Sciences InvestorsNYSE: HQL
Cost of Revenue · Q2 FY2026 · quarter ended Mar 2026
Cost of revenue grows 23.3% year over year
Q2 FY2026 cost of revenue of $3.12M rose 23.3% year over year. Over 3 fiscal years it compounded at -3.6% a year.
Context
- Cost of revenue amounted to 5.8% of revenue in FY2025, down 0.4 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 4.97M USD
- Year-over-year change
- -7.2%
- 4-year CAGR
- -4.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 4.97M | -7.2% |
| FY2024 | 2024-09-30 | 5.36M | +2.2% |
| FY2023 | 2023-09-30 | 5.24M | -5.5% |
| FY2022 | 2022-09-30 | 5.55M | -8.7% |
| FY2021 | 2021-09-30 | 6.08M | — |
Cost of Revenue vs competitors
How HQL compares with its peers on the latest reported figures
- HQL's FY2025 cost of revenue of $4.97M is the 8th highest of the 10 companies compared; the peer median is $39.68M.
- Its year-over-year change of -7.2% is the 5th highest of 9, against a peer median of -7.3%.
- Cost of revenue amounts to 5.8% of revenue for HQL, versus a peer median of 33.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $77.88M | -18.5% | +1.2% | 52.7% | |
| LTM Mar 2026 | $47.29M | +67.4% | +53.7% | 42.1% | |
| LTM Mar 2026 | $43.16M | -40.5% | — | 176.5% | |
| LTM Mar 2026 | $41.31M | -28.8% | +5.9% | 33.1% | |
| LTM Mar 2026 | $39.68M | -13.4% | +12.8% | 48.2% | |
| LTM Dec 2025 | $30.8M | +345.7% | +49.8% | 18.4% | |
| LTM Mar 2026 | $22.82M | +10.2% | +12.4% | 32.4% | |
| FY2025 | $4.97M | -7.2% | -3.6% | 5.8% | |
| FY2025 | $3.16M | -1.3% | +3.0% | 6.7% | |
| LTM Jun 2025 | $0 | — | +14.5% | 0.0% | |
| Peer median (excluding HQL) | $39.68M | -7.3% | +12.6% | 33.1% | |
Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 45.02M | 31.86M | 39.39M | 86.69M | 86.39M |
| Cost of Revenue | 6.08M | 5.55M | 5.24M | 5.36M | 4.97M |
| Gross Profit | 38.95M | 26.31M | 18.28M | 86.69M | 86.39M |
| Gross Margin | 86.5% | 82.6% | 46.4% | 100.0% | 100.0% |
| Research & Development | 0 | (3) | 0 | 0 | 0 |
| Selling, General & Admin | 844.02K | 1.08M | 903.14K | 1.33M | 743.17K |
| Operating Expenses | 1.16M | 1.35M | 1.17M | 1.39M | 791.57K |
| Depreciation & Amortization | 4.14M | 2.99M | 27.6M | 1.92M | 0 |
| EBITDA | 68.68M | (101.62M) | 49.95M | 87.22M | 85.59M |
| EBITDA Margin | 152.5% | -318.9% | 126.8% | 100.6% | 99.1% |
| Operating Income | 64.53M | (104.6M) | (5.24M) | 85.3M | 85.59M |
| Operating Margin | 143.3% | -328.3% | -13.3% | 98.4% | 99.1% |
| Interest Income | 0 | 50.09K | 204.45K | 1.04M | 349.84K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (7.83K) | 2.42K | 27.6M | 87.22M | 0 |
| Income Before Tax | 64.53M | (104.6M) | 22.35M | 85.3M | 85.59M |
| Pre-Tax Margin | 143.3% | -328.3% | 56.8% | 98.4% | 99.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 64.53M | (104.6M) | 22.35M | 85.3M | 85.59M |
| Net Margin | 143.3% | -328.3% | 56.8% | 98.4% | 99.1% |
| EPS (Basic) | 2.66 | (4.07) | 0.79 | 3.04 | 2.96 |
| EPS (Diluted) | 2.66 | (4.07) | 0.79 | 3.04 | 2.96 |
| Weighted Avg Shares | 24.26M | 25.68M | 28.29M | 28.06M | 28.87M |
| Weighted Avg Shares (Diluted) | 24.26M | 25.68M | 28.29M | 28.06M | 28.87M |
Tekla Life Sciences Investors
NYSE:HQL
Intrinsic Alpha fair value
Locked
Current Price
$19.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.